Development · 5 Nov 2026
SUNPHARMA, full dossier7 publishers have reported this development. Each act of reporting is below, cited.
Sun Pharmaceutical Industries Ltd reported a Net Profit of ₹1,995.07 crore, a 36.16 per cent year-on-year decline.
Sun Pharmaceutical Industries reported a 36.36 percent decline in consolidated net profit to Rs 1,988.53 crore for the September quarter.
Sun Pharmaceutical Industries reported 11.8% year-on-year growth in sales to ₹16,100 crore in Q2 FY27. Adjusted net profit stood at ₹3,162 crore, while reported net profit was ₹1,988.5 crore. EBITDA increased 4.8% to ₹4,743.9 crore, with an EBITDA margin of 29.3%.
Sun Pharmaceutical Industries reported a consolidated net profit of ₹1,988.53 crore for the July-September quarter, a 36.36% year-on-year decline from ₹3,124.95 crore in the same period last year.
Sun Pharma's net profit fell 36.2% to Rs 1,988.53 crore in the quarter ended September 2026, impacted by a one-time loss of Rs 1,269 crore.
Sun Pharmaceutical Industries reported a 36 per cent year-on-year decline in consolidated net profit to ₹1,988.5 crore for the second quarter of 2026-27, weighed down by exceptional charges.
Sun Pharmaceutical Industries posted 11.8 per cent year-on-year growth in operating revenues to Rs 16,100 crore in the second quarter ended September this year.
Sun Pharmaceutical Industries consolidated net profit declined 36.22% to Rs 1988.53 crore in the quarter ended September 2026.
Sun Pharma reported a 36.22 per cent year-on-year decline in consolidated net profit for the September quarter (Q2 FY27), with net profit standing at Rs 1,988.53 crore compared to Rs 3,117.95 crore in the corresponding quarter last year.
16 Nov 2026 · 1 publisher
Sun Pharmaceutical Industries Ltd is down for a fifth straight session.
16 Nov 2026 · 1 publisher
Bank of India is quoting at Rs 154.3, up 1.91% on the day as on 12:39 IST on the NSE.
14 Nov 2026 · 1 publisher
14 Nov 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.